blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3575794

EP3575794 - DETECTION AND TREATMENT OF CD30+ CANCERS [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  09.10.2020
Database last updated on 07.10.2024
FormerRequest for examination was made
Status updated on  05.06.2020
FormerThe application has been published
Status updated on  01.11.2019
Most recent event   Tooltip09.10.2020Application deemed to be withdrawnpublished on 11.11.2020  [2020/46]
Applicant(s)For all designated states
Seattle Genetics, Inc.
21823 30th Drive, S.E.
Bothell, WA 98021 / US
[2019/49]
Inventor(s)01 / ALBERTSON, Tina
c/o Seattle Genetics, Inc.
21823 30th Drive S.E.
Bothell, WA 98021 / US
02 / SMITH, Maria
c/o Seattle Genetics, Inc.
21823 30th Drive S.E.
Bothell, WA 98021 / US
 [2019/49]
Representative(s)Abel & Imray LLP
Westpoint Building
James Street West
Bath BA1 2DA / GB
[N/P]
Former [2019/49]Abel & Imray
Westpoint Building
James Street West
Bath BA1 2DA / GB
Application number, filing date19168115.408.02.2013
[2019/49]
Priority number, dateUS201261597547P10.02.2012         Original published format: US 201261597547 P
[2019/49]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3575794
Date:04.12.2019
Language:EN
[2019/49]
Search report(s)(Supplementary) European search report - dispatched on:EP26.08.2019
ClassificationIPC:G01N33/574, A61K39/395, A61K47/68, C07K16/28
[2019/49]
CPC:
G01N33/57492 (EP,CN,US); A61K47/6849 (EP,US); A61P35/00 (EP);
C07K16/2878 (EP,US); G01N2333/70578 (EP,CN,US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2020/28]
Former [2019/49]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
TitleGerman:DETEKTION UND BEHANDLUNG VON CD30+KARZINOMEN[2019/49]
English:DETECTION AND TREATMENT OF CD30+ CANCERS[2019/49]
French:DÉTECTION ET TRAITEMENT DES LYMPHOMES T À GRANDES CELLULES CD30+[2019/49]
Examination procedure03.06.2020Examination requested  [2020/28]
03.06.2020Date on which the examining division has become responsible
05.06.2020Application deemed to be withdrawn, date of legal effect  [2020/46]
26.06.2020Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time  [2020/46]
Parent application(s)   TooltipEP13746038.2  / EP2812702
Fees paidRenewal fee
09.04.2019Renewal fee patent year 03
09.04.2019Renewal fee patent year 04
09.04.2019Renewal fee patent year 05
09.04.2019Renewal fee patent year 06
09.04.2019Renewal fee patent year 07
27.02.2020Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[Y]US2010322920  (KELER TIBOR [US], et al) [Y] 11-15 * see [0009-0010, 0035, 0198-0201] *;
 [XYI]  - "Phase I study of HeFi-1 to treat cancers with CD30 protein", (20021111), National Institutes of Health Clinical Center, Maryland (US), URL: https//clinicaltrials.gov/ct2/show/NCT00048880, (20190813), XP002793543 [X] 1-3,6,8-10 * the whole document * [Y] 11-15 [I] 4,5,7
 [Y]  - RYOUICHI HORIE ET AL, "CD30: expression and function in health and disease", SEMINARS IN IMMUNOLOGY., US, (19981201), vol. 10, no. 6, doi:10.1006/smim.1998.0156, ISSN 1044-5323, pages 457 - 470, XP055396497 [Y] 11-15 * see p. 459, 461 *

DOI:   http://dx.doi.org/10.1006/smim.1998.0156
 [Y]  - J. KATZ ET AL, "Brentuximab Vedotin (SGN-35)", CLINICAL CANCER RESEARCH, US, (20111014), vol. 17, no. 20, doi:10.1158/1078-0432.CCR-11-0488, ISSN 1078-0432, pages 6428 - 6436, XP055612709 [Y] 11-15 * see p. 6428-6431 *

DOI:   http://dx.doi.org/10.1158/1078-0432.CCR-11-0488
 [Y]  - G Pallesen ET AL, "Ki-1 (CD3O) Antigen Is Regularly Expressed by Tumor Cells ofEmbryonal Carcinoma", American Journal of Pathology, (19881201), URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1880812/pdf/amjpathol00129-0028.pdf, (20190814), XP055483398 [Y] 11-15 * see p. 447 *
 [A]  - SCHWARTING R ET AL, "BER-H2: A NEW ANTI-KI-1 (CD30) MONOCLONAL ANTIBODY DIRECTED AT A FORMOL-RESISTANT EPITOPE", BLOOD,, (19891001), vol. 74, no. 5, ISSN 0006-4971, pages 1678 - 1689, XP009019046 [A] 1-15 * the whole document *
by applicantEP0000598
 EP0000877
 US4444887
 US4474893
 WO8605807
 EP0239400
 US4714681
 US4716111
 WO8901036
 US4816567
 US4816397
 WO9002809
 US4925648
 WO9007861
 US4946778
 WO9100360
 WO9109967
 WO9110741
 WO9110737
 WO9117271
 WO9201047
 WO9205793
 WO9208802
 US5122464
 WO9218619
 EP0519596
 WO9222324
 WO9311236
 US5223409
 US5225539
 WO9317715
 US5258498
 EP0592106
 US5403484
 US5413923
 WO9515982
 US5427908
 WO9520401
 US5516637
 US5530101
 US5545806
 US5565332
 US5569825
 WO9634096
 WO9633735
 US5571698
 US5573920
 US5580717
 US5585089
 US5601819
 US5625126
 US5633425
 US5658727
 US5661016
 US5698426
 US5733743
 WO9816654
 US5750753
 WO9824893
 US5780225
 US5807715
 US5814318
 US5821047
 WO9846645
 WO9850433
 US5885793
 US5888809
 US5916771
 US5939598
 US5969108
 US2009018086
 US7498298
 US2009111756
 US7659241
 US7968687
 US2012014943
    - FROESE et al., J. Immunol., (19870000), vol. 139, pages 2081 - 87
    - SCHWAB et al., Nature, (19820000), vol. 299, pages 65 - 67
    - TUTT et al., J. Immunol., (19910000), vol. 147, pages 60 - 69
    - KOSTELNY et al., J. Immunol., (19920000), vol. 148, pages 1547 - 1553
    - MORRISON, Science, (19850000), vol. 229, page 1202
    - OI et al., BioTechniques, (19860000), vol. 4, page 214
    - GILLIES et al., J. Immunol. Methods, (19890000), vol. 125, pages 191 - 202
    - RIECBMANN et al., Nature, (19880000), vol. 332, page 323
    - PADLAN, Molecular Immunology, (19910000), vol. 28, no. 4/5, pages 489 - 498
    - STUDNICKA et al., Protein Engineering, (19940000), vol. 7, no. 6, pages 805 - 814
    - ROGUSKA et al., PNAS, (19940000), vol. 91, pages 969 - 973
    - JESPERS et al., Biotechnology, (19940000), vol. 12, pages 899 - 903
    - LONBERG; HUSZAR, Int. Rev. Immunol., (19950000), vol. 13, pages 65 - 93
    - KOHLER et al., Nature, (19750000), vol. 256, page 495
    - QUEEN et al., Proc. Natl. Acad. Sci. USA, (19890000), vol. 86, pages 10029 - 10033
    - HAMMERLING et al., In Monoclonal Antibodies and T-Cell Hybridomas, Elsevier, (19810000), pages 563 - 681
    - BRIINNAN et al., J. Immunol. Methods, (19950000), vol. 182, pages 41 - 50
    - AMES et al., J. Immunol. Methods, (19950000), vol. 184, pages 177 - 186
    - KETTLEBOROUGH et al., Eur. J. Immunol., (19940000), vol. 24, pages 952 - 958
    - PERSIC et al., Gene, (19970000), vol. 187, pages 9 - 18
    - BURTON et al., Advances in Immunology, (19940000), vol. 57, pages 191 - 280
    - MULLINAX et al., BioTechniques, (19920000), vol. 12, no. 6, pages 864 - 869
    - SAWAI et al., AJRI, (19950000), vol. 34, pages 26 - 34
    - BETTER et al., Science, (19880000), vol. 240, pages 1041 - 1043
    - HUSTON et al., Methods in Enzymology, (19910000), vol. 203, pages 46 - 88
    - SHU et al., Proc. Natl. Acad. Sci. USA, (19930000), vol. 90, pages 7995 - 7999
    - SKERRA et al., Science, (19880000), vol. 240, pages 1038 - 1040
    - FOECKING et al., Gene, (19860000), vol. 45, page 101
    - COCKETT et al., BiolTechnology, (19900000), vol. 8, page 2
    - RUTHER et al., EMBO, (19830000), vol. 1, no. 2, page 1791
    - INOUYE; INOUYE, Nucleic Acids Res, (19850000), vol. 13, pages 3101 - 3109
    - VAN HEEKE; SCHUSTER, J. Biol. Chem., (19890000), vol. 24, pages 5503 - 5509
    - LOGAN; SHENK, Proc. Natl. Acad. Sci. USA, (19840000), vol. 81, pages 355 - 359
    - BITTNER et al., Methods in Enzymol, (19870000), vol. 153, pages 51 - 544
    - ALLEY et al., urrent Opinion in Chemical Biology, (20100000), vol. 14, pages 1 - 9
    - SENTER, Cancer J., (20080000), vol. 14, no. 3, pages 154 - 169
    - FOX et al., J. Histochem. Cytochem., (19850000), vol. 33, pages 845 - 853
    - SHI et al., J Histochem Cytochem, (19910000), vol. 39, pages 741 - 748
    - LANGER, Science, (19900000), vol. 249, pages 1527 - 1533
    - SEFTON, CRC Crit. Ref. Biomed. Eng., (19890000), vol. 14, page 201
    - BUCHWALD et al., Surgery, (19800000), vol. 88, page 507
    - SAUDEK, N. Engl. J. Med., (19890000), vol. 321, page 574
    - RANGER; PEPPAS, Macromol. Sci. Rev. Macromol. Chem., (19830000), vol. 23, page 61
    - LEVY et al., Science, (19850000), vol. 228, page 190
    - DURING et al., Ann. Neurol., (19890000), vol. 25, page 351
    - HOWARD et al., J. Neurosurg, (19890000), vol. 71, page 105
 WO1991GB01134
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.